<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01532921</url>
  </required_header>
  <id_info>
    <org_study_id>EASE TRICUSPID</org_study_id>
    <nct_id>NCT01532921</nct_id>
  </id_info>
  <brief_title>EASE TRICUSPID Expertise-based Assessment Study on Clinical Efficacy of Contour 3D® in TRICUSPID Valve Annuloplasty</brief_title>
  <official_title>EASE TRICUSPID Expertise-based Assessment Study on Clinical Efficacy of Contour 3D® in TRICUSPID Valve Annuloplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Bakken Research Center</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Cardiovascular</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Few clinical evidence for the Contour 3D Tricuspid Annuloplasty Ring exists; therefore, in
      order to position this product on the market, a post-market release study was completed. The
      purpose of this study was to evaluate the hemodynamic performance of the Contour 3D®
      Tricuspid Annuloplasty Ring following Tricuspid Valve (TV) repair in a post-market
      environment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The EASE TRICUSPID Clinical Trial was a prospective, non-randomized, non-interventional,
      post-market release study. The purpose of this study was to evaluate the hemodynamic
      performance of the Contour 3D® Tricuspid Annuloplasty Ring following Tricuspid Valve (TV)
      repair in a post-market environment. Therefore, the primary objective of the EASE Tricuspid
      Study was to evaluate the hemodynamic performance of the Contour 3D® Tricuspid Annuloplasty
      Ring (Contour 3D ring) in subjects with tricuspid regurgitation who had a clinical indication
      for TV repair in a post-market use. Secondary objectives included the evaluation of the
      effect of TV repair with the Contour 3D ring on the right ventricular function, as well as
      the assessment of the effect of TV repair with the Contour 3D ring on the functional status
      in subjects undergoing TV repair in a post-market environment. Subjects eligible for TV
      repair and compliant with the enrollment criteria were considered by the Investigator for
      inclusion in the study. To minimize bias, enrolled subjects were followed by their own
      physician in accordance with the center's established practice for routine follow up.
      Follow-up sessions were planned at the physician's discretion. To meet the intended goals,
      appropriate clinical data were collected at baseline (pre-surgery), during the surgical
      procedure, at discharge and during the follow-up period at 6 months. Experienced
      echo-cardiologists evaluated the echos. At the time of enrollment it was not certain if the
      subject would receive a Contour 3D ring, since the surgeon might have decided during surgery
      that another treatment was more beneficial to the subject. In this case, the subject was
      terminated from the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Gradient Across the Tricuspid Valve</measure>
    <time_frame>At Baseline, Discharge (up to 5 days post-implant) and 6 months post-implant</time_frame>
    <description>The mean gradient across the Tricuspid Valve (TV) measured via echocardiography at discharge (up to 5 days post-implant) through 6 months post-implant</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in the Degree of Tricuspid Regurgitation From Baseline Through Discharge (up to 5 Days Post-implant) and 6 Months Post-implant</measure>
    <time_frame>Baseline to Discharge (up to 5 days post-implant) and through 6 months post-implant</time_frame>
    <description>Change in the degree of tricuspid regurgitation measured via echocardiography from Baseline through 6 months post-implant. The severity of tricuspid regurgitation is graded by using several qualitative and quantitative methods. The degree of regurgitation is classified as &quot;none&quot;, &quot;Mild&quot;, &quot;Moderate&quot; or &quot;Severe&quot;.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Tricuspid Valve (TV) Leaflet Coaptation Length From Baseline Through 6 Months Post-implant</measure>
    <time_frame>Baseline to Discharge (up to 5 days post-implant) and to 6 months post-implant</time_frame>
    <description>Change in the degree of TV leaflet coaptation length measured via echocardiography from Baseline through 6 months post-implant</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in the Degree of Tricuspid Valve (TV) Leaflet Tethering Height From Baseline Through 6 Months Post-implant</measure>
    <time_frame>Baseline to Discharge (up to 5 days post-implant) and 6 months post-implant</time_frame>
    <description>Change in the degree of TV leaflet tethering height measured via echocardiography from Baseline through 6 months post-implant</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the Right Ventricle (RV) Diastolic Area From Baseline Through 6 Months Post-implant</measure>
    <time_frame>Basline to Discharge (up to 5 days post-implant) and 6 months post-implant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Tricuspid Annular Diameter Measured at Diastole From Baseline Through 6 Months Post-implant</measure>
    <time_frame>Baseline to Discharge (up to 5 days post-implant) and 6 months post-implant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Right Ventricle (RV) Fractional Area From Baseline Through 6 Months Post-implant</measure>
    <time_frame>Baseline to Discharge (up to 5 days post-implant) and 6 months post-implant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in New York Heart Association (NYHA) Classification From Baseline Through 6 Months Post-implant</measure>
    <time_frame>Baseline to Discharge (up to 5 days post-implant) and 6 months post-implant</time_frame>
    <description>The New York Heart Association (NYHA) Functional Classification provides a simple way of classifying the extent of heart failure. It places patients in one of four categories based on how much they are limited during physical activity; the limitations/symptoms are in regard to normal breathing and varying degrees in shortness of breath and/or angina. NYHA I implies no limitations. NYHA II implies slight limitation of physical activity. NYHA III implies marked limitation of physical activity and finally, NYHA IV implies patients are Unable to carry on any physical activity without discomfort.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">85</enrollment>
  <condition>Tricuspid Valve Insufficiency</condition>
  <arm_group>
    <arm_group_label>Subjects with Tricuspid Valve Repair</arm_group_label>
    <description>All patients indicated for a Tricuspid Valve (TV) repair procedure concomitantly to left-sided heart surgery, and for whom the surgeon considers the implantation of a Contour 3D® Tricuspid Annuloplasty Ring most appropriate to reconstruct the diseased valve.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Tricuspid valve repair</intervention_name>
    <arm_group_label>Subjects with Tricuspid Valve Repair</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Left-sided heart surgery</intervention_name>
    <description>Tricuspid valve repair was with the study device was only warranted if concomitant left-sided heart surgery was planned</description>
    <arm_group_label>Subjects with Tricuspid Valve Repair</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Contour 3D Tricuspid Annuloplasty Ring</intervention_name>
    <description>Contour 3D Tricuspid Annuloplasty procedure was used during the tricuspid valve repair</description>
    <arm_group_label>Subjects with Tricuspid Valve Repair</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The patient population includes all patients indicated for a TV repair procedure
        concomitantly to left-sided heart surgery, and for whom the surgeon considers the
        implantation of a Contour 3D® Tricuspid Annuloplasty Ring most appropriate to reconstruct
        the diseased valve. Patients with primary TV are not included, since this is often
        characterized by pathological leaflets for which the Contour 3D® Tricuspid Annuloplasty
        Ring would not be beneficial.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing to sign and date the Patient Informed Consent (PIC)

          -  Indicated for a concomitant surgical repair of the TV

          -  Willing to return to the hospital, where the implantation originally occurred, for a 6
             month follow-up visit

        Exclusion Criteria:

          -  Patients with a degenerative TV condition

          -  Patients with primary TV regurgitation

          -  Previous TV repair or replacement

          -  Stand-alone TV repair

          -  Already participating in another investigational device or drug study, possibly
             leading to bias and jeopardizing the scientific appropriate assessment of the study
             endpoints

          -  Life expectancy of less than one year

          -  Pregnant or desire to be pregnant within 12 months of the study treatment

          -  Under 18 years or over 85 years of age

          -  Patients with active endocarditis

          -  Patients with valvular retraction with severely reduced mobility

          -  Patients with a heavily calcified TV
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rüdiger Lange, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Deutsches Herzzentrum München</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital de Lyon - Hôpital Louis Pradel</name>
      <address>
        <city>Lyon</city>
        <zip>69500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Mulhouse</name>
      <address>
        <city>Mulhouse</city>
        <zip>68100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albertinen Herz- und Gefäßzentrum</name>
      <address>
        <city>Hamburg</city>
        <zip>22457</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein</name>
      <address>
        <city>Lübeck</city>
        <zip>23562</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deutsches Herzzentrum München</name>
      <address>
        <city>Munich</city>
        <zip>D-80636</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soroka Medical Center</name>
      <address>
        <city>Be'er Sheeva</city>
        <zip>84101</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shaare Zedek Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
  </location_countries>
  <removed_countries>
    <country>Netherlands</country>
  </removed_countries>
  <link>
    <url>http://www.medtronic.com</url>
    <description>Sponsor Website</description>
  </link>
  <verification_date>November 2017</verification_date>
  <study_first_submitted>February 10, 2012</study_first_submitted>
  <study_first_submitted_qc>February 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2012</study_first_posted>
  <results_first_submitted>June 16, 2017</results_first_submitted>
  <results_first_submitted_qc>November 16, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 10, 2018</results_first_posted>
  <last_update_submitted>November 16, 2017</last_update_submitted>
  <last_update_submitted_qc>November 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tricuspid Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Indicated for a TV Repair Procedure</title>
          <description>All patients indicated for a TV repair procedure concomitantly to left-sided heart surgery, and for whom the surgeon considers the implantation of a Contour 3D® Tricuspid Annuloplasty Ring most appropriate to reconstruct the diseased valve.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="85"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Implantation Procedure</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Discharge</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>6 Months Follow Up</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="69"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Device was explanted during procedure</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline data include all subjects who underwent the implant procedure of the study device</population>
      <group_list>
        <group group_id="B1">
          <title>Indicated for a TV Repair Procedure</title>
          <description>All patients indicated for a TV repair procedure concomitantly to left-sided heart surgery, and for whom the surgeon considers the implantation of a Contour 3D® Tricuspid Annuloplasty Ring most appropriate to reconstruct the diseased valve.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="76"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.2" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>EuroSCORE II percentage score</title>
          <description>EuroSCORE II (European System for Cardiac Operative Risk Evaluation) is a risk model that allows the calculation of the risk of death after a heart operation. The higher the score, the higher the risk of death after surgery. The included risk factors are: age, gender, renal impairment, extracardiac arteriopathy, poor mobility, previous cardiac surgery, chronic lung disease, active endocarditis, critical preoperative state, diabetes on insulin, NYHA-class, CCS Class 4 Angina, Left ventricular function, recent myocardial infarction, pulmonary hypertension and 3 procedure-related factors.</description>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.7" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>NYHA Class</title>
          <description>The New York Heart Association (NYHA) Functional Classification provides a simple way of classifying the extent of heart failure. It places patients in one of four categories based on how much they are limited during physical activity; the limitations/symptoms are in regard to normal breathing and varying degrees in shortness of breath and/or angina. NYHA I implies no limitations. NYHA II implies slight limitation of physical activity. NYHA III implies marked limitation of physical activity and finally, NYHA IV implies patients are Unable to carry on any physical activity without discomfort.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>NYHA Class I</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>NYHA Class II</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>NYHA Class III</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>NYHA Class IV</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Gradient Across the Tricuspid Valve</title>
        <description>The mean gradient across the Tricuspid Valve (TV) measured via echocardiography at discharge (up to 5 days post-implant) through 6 months post-implant</description>
        <time_frame>At Baseline, Discharge (up to 5 days post-implant) and 6 months post-implant</time_frame>
        <population>Implanted cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
            <description>All enrolled patients indicated for a TV repair procedure concomitantly to left-sided heart surgery, and for which the surgeon considers the implantation of a Contour 3D® Tricuspid Annuloplasty Ring most appropriate to reconstruct the diseased valve.</description>
          </group>
          <group group_id="O2">
            <title>Discharge (up to 5 Days Post-implant)</title>
            <description>All enrolled patients indicated for a TV repair procedure concomitantly to left-sided heart surgery, and for which the surgeon considers the implantation of a Contour 3D® Tricuspid Annuloplasty Ring most appropriate to reconstruct the diseased valve.</description>
          </group>
          <group group_id="O3">
            <title>6 Months Follow-Up</title>
            <description>All enrolled patients indicated for a TV repair procedure concomitantly to left-sided heart surgery, and for which the surgeon considers the implantation of a Contour 3D® Tricuspid Annuloplasty Ring most appropriate to reconstruct the diseased valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Gradient Across the Tricuspid Valve</title>
          <description>The mean gradient across the Tricuspid Valve (TV) measured via echocardiography at discharge (up to 5 days post-implant) through 6 months post-implant</description>
          <population>Implanted cohort</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="0.6"/>
                    <measurement group_id="O2" value="2.0" spread="1.0"/>
                    <measurement group_id="O3" value="1.9" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in the Degree of Tricuspid Regurgitation From Baseline Through Discharge (up to 5 Days Post-implant) and 6 Months Post-implant</title>
        <description>Change in the degree of tricuspid regurgitation measured via echocardiography from Baseline through 6 months post-implant. The severity of tricuspid regurgitation is graded by using several qualitative and quantitative methods. The degree of regurgitation is classified as &quot;none&quot;, &quot;Mild&quot;, &quot;Moderate&quot; or &quot;Severe&quot;.</description>
        <time_frame>Baseline to Discharge (up to 5 days post-implant) and through 6 months post-implant</time_frame>
        <population>Implanted cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Discharge (up to 5 Days Post-implant)</title>
            <description>All enrolled patients indicated for a TV repair procedure concomitantly to left-sided heart surgery, and for which the surgeon considers the implantation of a Contour 3D® Tricuspid Annuloplasty Ring most appropriate to reconstruct the diseased valve.</description>
          </group>
          <group group_id="O2">
            <title>6 Months Follow-Up</title>
            <description>All enrolled patients indicated for a TV repair procedure concomitantly to left-sided heart surgery, and for which the surgeon considers the implantation of a Contour 3D® Tricuspid Annuloplasty Ring most appropriate to reconstruct the diseased valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Degree of Tricuspid Regurgitation From Baseline Through Discharge (up to 5 Days Post-implant) and 6 Months Post-implant</title>
          <description>Change in the degree of tricuspid regurgitation measured via echocardiography from Baseline through 6 months post-implant. The severity of tricuspid regurgitation is graded by using several qualitative and quantitative methods. The degree of regurgitation is classified as &quot;none&quot;, &quot;Mild&quot;, &quot;Moderate&quot; or &quot;Severe&quot;.</description>
          <population>Implanted cohort</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Improved 4 grades</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Improved 3 grades</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Improved 2 grades</title>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Improved 1 grade</title>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No change</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsened 2 grades</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsened 3 grades</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsened 4 grades</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Tricuspid Valve (TV) Leaflet Coaptation Length From Baseline Through 6 Months Post-implant</title>
        <description>Change in the degree of TV leaflet coaptation length measured via echocardiography from Baseline through 6 months post-implant</description>
        <time_frame>Baseline to Discharge (up to 5 days post-implant) and to 6 months post-implant</time_frame>
        <population>Implanted cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Discharge (up to 5 Days Post-implant)</title>
            <description>All enrolled patients indicated for a TV repair procedure concomitantly to left-sided heart surgery, and for which the surgeon considers the implantation of a Contour 3D® Tricuspid Annuloplasty Ring most appropriate to reconstruct the diseased valve.</description>
          </group>
          <group group_id="O2">
            <title>6 Months Follow-Up</title>
            <description>All enrolled patients indicated for a TV repair procedure concomitantly to left-sided heart surgery, and for which the surgeon considers the implantation of a Contour 3D® Tricuspid Annuloplasty Ring most appropriate to reconstruct the diseased valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Tricuspid Valve (TV) Leaflet Coaptation Length From Baseline Through 6 Months Post-implant</title>
          <description>Change in the degree of TV leaflet coaptation length measured via echocardiography from Baseline through 6 months post-implant</description>
          <population>Implanted cohort</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="4.6"/>
                    <measurement group_id="O2" value="0.0" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in the Degree of Tricuspid Valve (TV) Leaflet Tethering Height From Baseline Through 6 Months Post-implant</title>
        <description>Change in the degree of TV leaflet tethering height measured via echocardiography from Baseline through 6 months post-implant</description>
        <time_frame>Baseline to Discharge (up to 5 days post-implant) and 6 months post-implant</time_frame>
        <population>Implanted cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Discharge (up to 5 Days Post-implant)</title>
            <description>All enrolled patients indicated for a TV repair procedure concomitantly to left-sided heart surgery, and for which the surgeon considers the implantation of a Contour 3D® Tricuspid Annuloplasty Ring most appropriate to reconstruct the diseased valve.</description>
          </group>
          <group group_id="O2">
            <title>6 Months Follow-Up</title>
            <description>All enrolled patients indicated for a TV repair procedure concomitantly to left-sided heart surgery, and for which the surgeon considers the implantation of a Contour 3D® Tricuspid Annuloplasty Ring most appropriate to reconstruct the diseased valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Degree of Tricuspid Valve (TV) Leaflet Tethering Height From Baseline Through 6 Months Post-implant</title>
          <description>Change in the degree of TV leaflet tethering height measured via echocardiography from Baseline through 6 months post-implant</description>
          <population>Implanted cohort</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="5.3"/>
                    <measurement group_id="O2" value="-0.5" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Right Ventricle (RV) Diastolic Area From Baseline Through 6 Months Post-implant</title>
        <time_frame>Basline to Discharge (up to 5 days post-implant) and 6 months post-implant</time_frame>
        <population>Implanted Cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Discharge (up to 5 Days Post-implant)</title>
            <description>All enrolled patients indicated for a TV repair procedure concomitantly to left-sided heart surgery, and for which the surgeon considers the implantation of a Contour 3D® Tricuspid Annuloplasty Ring most appropriate to reconstruct the diseased valve.</description>
          </group>
          <group group_id="O2">
            <title>6 Months Follow-Up</title>
            <description>All enrolled patients indicated for a TV repair procedure concomitantly to left-sided heart surgery, and for which the surgeon considers the implantation of a Contour 3D® Tricuspid Annuloplasty Ring most appropriate to reconstruct the diseased valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Right Ventricle (RV) Diastolic Area From Baseline Through 6 Months Post-implant</title>
          <population>Implanted Cohort</population>
          <units>mm2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="160.5" spread="481.3"/>
                    <measurement group_id="O2" value="50.0" spread="406.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Tricuspid Annular Diameter Measured at Diastole From Baseline Through 6 Months Post-implant</title>
        <time_frame>Baseline to Discharge (up to 5 days post-implant) and 6 months post-implant</time_frame>
        <population>Data were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Discharge (up to 5 Days Post-implant)</title>
            <description>All enrolled patients indicated for a TV repair procedure concomitantly to left-sided heart surgery, and for which the surgeon considers the implantation of a Contour 3D® Tricuspid Annuloplasty Ring most appropriate to reconstruct the diseased valve.</description>
          </group>
          <group group_id="O2">
            <title>6 Months Follow-Up</title>
            <description>All enrolled patients indicated for a TV repair procedure concomitantly to left-sided heart surgery, and for which the surgeon considers the implantation of a Contour 3D® Tricuspid Annuloplasty Ring most appropriate to reconstruct the diseased valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Tricuspid Annular Diameter Measured at Diastole From Baseline Through 6 Months Post-implant</title>
          <population>Data were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Right Ventricle (RV) Fractional Area From Baseline Through 6 Months Post-implant</title>
        <time_frame>Baseline to Discharge (up to 5 days post-implant) and 6 months post-implant</time_frame>
        <population>Implanted cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Discharge (up to 5 Days Post-implant)</title>
            <description>All enrolled patients indicated for a TV repair procedure concomitantly to left-sided heart surgery, and for which the surgeon considers the implantation of a Contour 3D® Tricuspid Annuloplasty Ring most appropriate to reconstruct the diseased valve.</description>
          </group>
          <group group_id="O2">
            <title>6 Months Follow-Up</title>
            <description>All enrolled patients indicated for a TV repair procedure concomitantly to left-sided heart surgery, and for which the surgeon considers the implantation of a Contour 3D® Tricuspid Annuloplasty Ring most appropriate to reconstruct the diseased valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Right Ventricle (RV) Fractional Area From Baseline Through 6 Months Post-implant</title>
          <population>Implanted cohort</population>
          <units>percentage of change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="13.4"/>
                    <measurement group_id="O2" value="-1.0" spread="17.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in New York Heart Association (NYHA) Classification From Baseline Through 6 Months Post-implant</title>
        <description>The New York Heart Association (NYHA) Functional Classification provides a simple way of classifying the extent of heart failure. It places patients in one of four categories based on how much they are limited during physical activity; the limitations/symptoms are in regard to normal breathing and varying degrees in shortness of breath and/or angina. NYHA I implies no limitations. NYHA II implies slight limitation of physical activity. NYHA III implies marked limitation of physical activity and finally, NYHA IV implies patients are Unable to carry on any physical activity without discomfort.</description>
        <time_frame>Baseline to Discharge (up to 5 days post-implant) and 6 months post-implant</time_frame>
        <population>Implanted cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Discharge (up to 5 Days Post-implant)</title>
            <description>All enrolled patients indicated for a TV repair procedure concomitantly to left-sided heart surgery, and for which the surgeon considers the implantation of a Contour 3D® Tricuspid Annuloplasty Ring most appropriate to reconstruct the diseased valve.</description>
          </group>
          <group group_id="O2">
            <title>6 Months Follow-Up</title>
            <description>All enrolled patients indicated for a TV repair procedure concomitantly to left-sided heart surgery, and for which the surgeon considers the implantation of a Contour 3D® Tricuspid Annuloplasty Ring most appropriate to reconstruct the diseased valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in New York Heart Association (NYHA) Classification From Baseline Through 6 Months Post-implant</title>
          <description>The New York Heart Association (NYHA) Functional Classification provides a simple way of classifying the extent of heart failure. It places patients in one of four categories based on how much they are limited during physical activity; the limitations/symptoms are in regard to normal breathing and varying degrees in shortness of breath and/or angina. NYHA I implies no limitations. NYHA II implies slight limitation of physical activity. NYHA III implies marked limitation of physical activity and finally, NYHA IV implies patients are Unable to carry on any physical activity without discomfort.</description>
          <population>Implanted cohort</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Improved 3 classes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Improved 2 classes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Improved 1 class</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No change</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsened 1 class</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsened 2 classes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsened 3 classes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 Months Follow-up period</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Adverse Events Within 6 Months of Implant Procedure</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrioventricular Block, Complete</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Pericardial Effusion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Atrial Tachycardia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Congestive</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Coronary Artery Occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Mitral Valve Incompetence</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Sinus Node Dysfunction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Ventricular Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Ventricular Septal Defect</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Pupils Unequal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Retroperitoneal Haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Impaired Healing</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Multi-Organ Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacterial Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Mediastinitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Septic Shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Postoperative Thoracic Procedure Complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Traumatic Lung Injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Ejection Fraction Decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Kidney injury</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Pericardial Effusion</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Transfusion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ber Kleijnen</name_or_title>
      <organization>Medtronic, Bakken Research Center Coronary and Structural Heart Disease Management (CSH), Endepolsdomein 5, 6229 GW Maastricht, The Netherlands</organization>
      <phone>+3143356 6566</phone>
      <email>ber.kleijnen@medtronic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

